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Abstract Approximately 20% of individuals with Parkinson's
disease (PD) report a positive family history. Yet, a large
portion of causal and disease-modifying variants is still
unknown. We used exome sequencing in two affected
individuals from a family with late-onset PD to identify 15
potentially causal variants. Segregation analysis and frequency
assessment in 862 PD cases and 1,014 ethnically matched
controls highlighted variants in EEF1D and LRRK1 as the best
candidates. Mutation screening of the coding regions of these
genes in 862 cases and 1,014 controls revealed several novel
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non-synonymous variants in both genes in cases and controls.
An in silico multi-model bioinformatics analysis was used to
prioritize identified variants in LRRK1 for functional follow-
up. However, protein expression, subcellular localization, and
cell viability were not affected by the identified variants.
Although it has yet to be proven conclusively that variants in
LRRK1 are indeed causative of PD, our data strengthen a
possible role for LRRK1 in addition to LRRK2 in the genetic
underpinnings of PD but, at the same time, highlight the
difficulties encountered in the study of rare variants identified
by next-generation sequencing in diseases with autosomal
dominant or complex patterns of inheritance.
Keywords Parkinson's disease . LRRK1 .EEF1D . Exome
sequencing
Introduction
Characterized by resting tremor, bradykinesia, rigidity, and
postural instability, Parkinson's disease (PD) is a prominent
neurodegenerative disorder. Genetic factors contribute to the
risk of PD—both sporadic and familial. Although up to 20 %
of PD cases are believed to be familial [1, 2], thus far, rare
genetic variants in only a few genes have been unequivocally
shown to underlie these familial forms. They include PARK2 /
PARKIN , PINK1 , PARK7 /DJ-1 , SNCA , and LRRK2 [3–8].
While all of these were identified by classical linkage analysis
in large, multi-generation families, recently, next-generation
sequencing has enabled the identification of disease-causing
variants in smaller families and—what is especially important
with regard to the investigation of neurodegenerative
conditions with an onset late in life—without the need of
genotypic information from more than one generation of
affected individuals. Recently, exome sequencing was used
to identify VPS35 as an additional gene involved in late-onset
familial PD [9, 10]. Still, to date, the identified genes only
explain a small portion of the genetic burden in familial PD. It
is likely that genetic factors involved in bringing about the PD
phenotype comprise both genetic variants of strong effect as
well as variants of weaker effect which contribute to disease
risk or phenotypic modification. A thorough understanding of
the entire spectrum of genetic alterations implicated in the
disease is necessary to better understand disease pathogenesis
and to provide more specific treatment options in the future.
Here, we describe whole exome sequencing in a German
family with autosomal dominant late-onset PD in whom
known PD-linked mutations has previously been excluded in
an attempt to pinpoint the disease-causing genetic variant.
Two variants in leucine-rich repeat kinase 1 (LRRK1) and
eukaryotic translation elongation factor 1 delta (EEF1D )
emerged as the best candidate variants.
Materials and methods
Participants
The family was evaluated by neurologists specializing in
movement disorders. All family members received a detailed
neurologic exam. Information on deceased family members
was gathered from medical and family records. Cases and
controls used in genotyping and variant screening have been
reported previously [9, 11] and are described in more detail in
the supplement. Ethics review board approval and
participants' written informed consent were obtained prior to
the initiation of the study.
Analysis of copy number variation
Genome-wide copy number variant (CNV) analysis was
carried out using Affymetrix Whole-Genome 2.7 M Array in
conjunction with the Chromosome Analysis Suite with a
confidence index of 85, a minimum homozygous region size
of 10 kb and a minimum probe count of 5.
Exome sequencing
Exome sequencing was performed on a Genome Analyzer IIx
(Illumina) after in-solution enrichment of exonic sequences
(SureSelect Human All Exon 38 Mb kit, Agilent). For both
samples, two lanes of a flow cell were sequenced, each as 54-
bp paired-end runs. Read alignment was carried out with
BWA (version 0.5.8) to the human genome assembly hg19.
Single nucleotide variants (SNVs) and small insertions and
deletions (indels) were detected with SAMtools (version
0.1.7). Prior to exome sequencing, presumably causal
mutations in known Parkinson's disease genes (SNCA ,
PARK2 , DJ1 , PINK1 , and LRRK2 (p.G2019S only)) had
been excluded. Moreover, no known PD-linked variants were
identified in either V:8 or V:17 by exome sequencing.
Genotyping
All 15 candidate variants were genotyped in 862 cases (376 of
German (age 71.1±9.4 years, 31.6 % female) and 486 of
Austrian (age 58.7±11.3 years, 35.4 % female) origin) and
1,014 population-based controls pertaining to the KORA-
AGE cohort (age 76±6.6 years, 50.1 % female) using
MALDI-TOF mass spectrometry on the Sequenom®
platform. Association was tested using the allelic test in
PLINK.
Variant screening
We used Idaho®'s LightScanner high-resolution melting curve
analysis to screen the eight coding exons of EEF1D for
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variants in the same set of 862 cases and 1,014 controls. For
technical reasons, a part of exon 3 of EEF1D could not be
evaluated. For LRRK1 , the ras of complex proteins (ROC,
p.631 to 826), the C-terminal of ROC (COR, p.827 to 1241),
and the kinase (p.1242 to 1525) domains as determined by an
InterproScan sequence search or extracted from the literature
[12] were screened. In the case of altered melting patterns
suggestive of variants, Sanger sequencing ensued.
Significance was judged using the χ2 test.
Bioinformatic prioritization of variants
We collected a set of reference SNVs known to impair
LRRK1 function. After computing a multiple sequence
alignment using ClustalW based on LRRK1 /LRRK2 pairs in
18 organisms, we introduced mutations into LRRK1 which
mimic non-synonymous LRRK2 mutations related to PD
(rs33939927 (p.Arg1441Gly), rs35801418 (p.Tyr1699Cys),
rs34637584 (p.Gly2019Ser), rs35870237 (p.Ile2020Thr)),
and added LRRK1 variants with a reported functional impact
[12] to the set of reference SNVs. An in silico approach was
applied to determine the disease potential of reference SNVs
and the novel, non-synonymous LRRK1 variants. To reduce
the error rates of single models in predicting the functional
effect of a given variant on the protein, we implemented a
multi-model ensemble combining prediction results of six
publically available prediction algorithms into a combined
Pscore (Fig. 3a, online methods). Additionally, a Dscore was
computed, scoring the severity of structural changes between
the wild type and the variant peptide based on the mean square
deviation (online methods). By combining the Pscore and the
Dscore, we computed a single overall mutation score
(Mscore), rating the disease potential of an SNV between 0
(harmless polymorphism) and 1 (disease mutation) (online
methods). SNVs were then ranked by their Mscore, and
hierarchical clustering was conducted by Ward's minimum
variance agglomeration method and Euclidean distance
matrix and analyzed in R ; p values were calculated by
multi-scale bootstrap resampling [13]. Also see supplement.
Cellular analyses
Cellular analyses were carried out as previously described
[14]. For a detailed description, see supplement.
Results
Pedigree and clinical phenotype
We describe a five-generation family from Southern Germany
in which six members were affected by PD and the pattern of
inheritance seems to be autosomal dominant with reduced
penetrance (Fig. 1). Clinical assessment revealed a tremor-
dominant, levodopa-responsive Parkinson's syndrome with an
age of onset at 56.7±1.15 years in all living affected
individuals (V:8, V:9, and V:17, Online Resources Tabl 1).
Further, all three affected individuals also showed positive
Babinski signs and suffered episodes of depression. Mild to
moderate cognitive impairment especially with regard to
visuoconstruction, memory, and attention was present in all
individuals. Dopamine transporter SPECT (DAT-SPECT)
performed in two affected individuals (V:8 and V:17) revealed
reduced tracer uptake in the putamen and asymmetrically in
the caudate nucleus, in line with a diagnosis of PD.
The affected parent and aunt (IV:5 and IV:7) of the proband
died before initiation of the study. An additional cousin, V:1,
had Parkinson's syndrome but also suffered from multiple
sclerosis. She also died before initiation of the study. Lastly,
a second cousin removed by four generations is also known to
suffer from late-onset PD. The prevalence of PD in the general
population is approximately 1 % [15]. Accordingly, we
expected to find at least one phenocopy in this extended
pedigree of 114 individuals. Since no additional family
members on her side of the family showed signs of PD and
since she shared none of the candidate variants common to the
other three affected individuals examined, we concluded that
it is unlikely that PD in her case is due to the same genetic
variant as in the other affected individuals.
Identification of candidate variants by exome sequencing
and segregation analysis
A genome-wide CNV scan revealed no structural variation≥
10 kb common to two affected members of the family (V:8
and V:17, Fig. 1). Exome sequencing was performed for the
same individuals. This generated 6.57 gigabases (Gb) of
alignable sequence for V:8 (average coverage=70.93, >8×
coverage=90.65 %) and 6.67 Gb for V:17 (average
coverage=76.29, >8× coverage=92.23 %). All detected
variants shared by the two affected individuals (16,283
variants) were filtered against variants annotated in dbSNP132
as well as in-house exomes (n =1076) of individuals with
unrelated diseases and variants with a minor allele frequency
(MAF)≥0.01 were excluded from the follow-up, leaving 71
coding variants. Of these, 36 variants were predicted to alter
the amino acid sequence (i.e., missense, nonsense, stop-loss,
splice site, or frameshift variants and indels) and were
genotyped in a third affected individual (V:9) (Online
Resources Fig 1). Fifteen variants in 15 genes were present
in all three affected individuals and were pursued further by
Sanger sequencing-based testing for segregation in 32
members of the family belonging to generation V. Under the
assumption that a given variant would be causal for PD,
penetrances ranged between 30 and 50 %, with variants in
Neurogenetics
LRRK1 , EEF1D , and ARHGAP39 reaching the highest
predicted penetrances (Table 1).
Frequency assessment of candidate variants in a case/control
cohort
We genotyped the remaining 15 variants in a case/control
sample, consisting of 862 individuals with PD and 1,014
KORA-AGE general population controls (Table 1). Two
assays (UGT1A9 p.Val167Ala, TUBB6 p.Thr275Ala) did
not meet quality control thresholds and were excluded from
the analysis. The remaining 13 variants were, overall, very
rare. Six (EEF1D p.Ala549Val, MUC17 p.Gln4310X,
CCDC60 p.Arg155His, NAAA p.Arg211Trp, PTPRN2
p.Glu317Lys, and GLP2R p.Ile61Met) were validated in the
proband but were otherwise not found again in the 1,876
individuals tested. FCGBP p.Glu4657fs was present in one
additional PD patient but not in controls, and ZNF438
p.Thr454Ile was found in the proband and one control. Four
additional variants annotated in dbSNP132 were identified at
similar frequencies in cases and controls (ARHGAP39
p.Arg667Gln and MFSD3 p.Met311Thr) or were more
common in controls than in cases (AQP4 p.Met202Thr and
BRCA2 p.The1524Val). LRRK1 p.Arg1261Gln was found in
eight controls and in four cases of our case/control sample
(MAF 0.23/0.40 %). However, in four other control samples
(680 additional KORA general population controls (0.07 %),
1,076 in-house exomes (0.05 %), 1,000 genomes (0.00 %),
and NHLBI-ESP exomes (0.09 %)), MAFs were significantly
lower, and the variant was, therefore, also analyzed further.
Mutational screening of EEF1D and LRRK1 in case/control
cohort
While no single clear candidate for a causal variant emerged,
two genes—EEF1D and LRRK1—were interesting with
regard to functional considerations and predicted penetrance
for PD in the family. The translation machinery has recently
been implicated in PD pathogenesis [16, 17]. Also, the
EEF1D p.Ala549Val variant was not found again in 3,064
individuals (genotyping cohort plus in-house exomes) and
was also not annotated in the 1000 Genomes database.
LRRK1 , the paralog of the well-established PD gene LRRK2 ,
has been shown to regulate endosomal protein transport, thus
linking it to the lysosomal pathway [18] which may be
compromised in PD [19, 20]. Formation of heterodimers
between LRRK1 and LRRK2 has also been reported [21,
22]. We screened the coding regions of these genes in 862
Austrian and German PD cases and 1,014 controls searching
for additional variants. This cohort comprised the same
individuals used for the above frequency assessment of exome
variants. We identified seven (six non-synonymous, one del)
novel variants predicted to change the amino acid sequence of
EEF1D . These were rare and occurred with similar
frequencies in cases (five individuals with a variant) and
controls (four individuals with a variant) (p >0.5, χ2 test,
Online Resources Tab 2). Variants did not cluster in a specific
part of the gene (Fig. 2). The ROC, COR, and kinase domains
of LRRK1 harbored a total of 20 novel amino acid sequence-
changing variants (19 non-synonymous, 1 del) and 2
previously reported non-synonymous variants (rs56003881,
rs41531245). Variants were found at similar frequencies in
both groups (30 in cases, 31 in controls) (p >0.5, χ2 test,
Online Resources Tab 2). While small numbers preclude
quantitative analyses, it is noteworthy that within the first
20 bp of the kinase domain, variants were present in both
cases and controls, while beyond p.1262, all non-synonymous
variants identified in the kinase domain occurred in cases only
(Fig. 2). None of the individuals harboring LRRK1 variants
were also positive for known LRRK2 variants p.Arg1441Cys,
p.Tyr1699Cys, p.Gly2019Ser, or p.Ile2020Thr.
Prioritization of LRRK1 variants using a novel bioinformatics
algorithm
Since heterodimer formation between LRRK1 and LRRK2 has
been described [21, 22], we decided to further assess the
identified variants in LRRK1 . To this end, we used a novel
bioinformatics algorithm based on a multi-model ensemble of
prediction algorithms and structural analysis to select variants
in LRRK1 for functional follow-up. Mutation scores were
calculated for the 19 novel, non-synonymous LRRK1 variants
identified in both cases and controls, the LRRK1 variants
(p.Lys746Glu, p.Phe1022Cys, p.Gly1411Arg and
p.Ile1412Thr) corresponding to four known pathogenic
LRRK2 mutations (p.Arg1441Gly, p.Tyr1699Cys,
Fig. 1 Pedigree of family used for exome sequencing. Open symbols indicate unaffected family members; affected individuals are denoted by closed
symbols . An arrow denotes the proband. Sexwas obscured and birth order was altered to protect privacy. A diagonal line indicates a deceased individual
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p.Gly2019Ser, and p.Ile2020Thr) and three artificial variants
known to abolish LRRK1 GTP-binding (p.Lys651Ala) and
kinase activity (p.Lys746Gly and p.Lys1270Trp) (Fig. 3a)
[12]. Hierarchical clustering showed that three of the novel
variants (p.Arg631Trp, p.Arg1271His and p.Tyr1410Asp)—
present only in PD cases—clustered with the LRRK1
equivalents of LRRK2 p.Arg1441Gly, p.Tyr1699Cys,
p.Gly2019Ser, and p.Ile2020Thr as well as the kinase- and
GTP-binding dead amino acid substitutions (Fig. 3b).
Accordingly, these three variants in addition to the initial
variant identified by exome sequencing (p.Arg1261Gln) were
selected for functional follow-up.
LRRK1
13 LRRs Roc4 ANK
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p.Arg1261Gln* 
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p.Arg1259Gln
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p.Ala549Val* 
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Fig. 2 Location of EEF1D and
LRRK1 variants identified in
variant screening in relation to
known functional domains. An
asterisk denotes the variant
identified by exome sequencing
Variants printed in blue and
annotated above the gene were
found in cases, variants in green
and below the gene were found in
controls
Fig. 3 Prediction of pathogenic potential of newly identified variants. a
For each variant (colored lines) the predicted score s of an individual
algorithm, its reliability r, and the transformed score p(s , r, c) are shown.
Variants holding a predicted disease-causing potential (class=1) were
respectively marked with an asterisk . The diverse results among each
single algorithm motivated the calculation of one combined score
(Pscore), which was adjusted by additional structural analyses (Dscore)
resulting in a mutation score (Mscore). The highest scoring variant is
p.Tyr1410Asp (Mscore=0.839), a variant only present in PD cases,
followed by the LRRK2 equivalent of Gly2019Ser (Mscore=0.771), the
loss of autophosphorylation mutation Lys1270Trp (Mscore=0.768), and
two variants abolishing kinase activity: Ile1412Thr (Mscore=0.728) and
Lys746Gly (Mscore=0.723). b Hierarchical clustering with Ward's
minimum variance agglomeration method and Euclidean distance matrix
shows that three of the novel variants which were only found in
individuals with PD (p.Arg631Trp, p.Arg1271His, and p.Tyr1410Asp)
cluster with the LRRK1 equivalents of LRRK2 p.Arg1441Gly,
p.Tyr1699Cys, p.Gly2019Ser, and p.Ile2020Thr as well as the LRRK1
kinase- and GTP-binding dead amino acid substitutions
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Functional assessment of LRRK1 variants
In SHSY5Y neuroblastoma cells, levels of protein expression
as assessed by Western blot were not changed by any of the
four newly identified variants or the artificial variants ablating
GTP-b ind ing (p .Lys651Ala ) or k inase ac t iv i ty
(p.Lys1270Trp) (Fig. 4a). Likewise, the presence of these
variants was not associated with significant toxicity as
measured by MTT assay (Fig. 4b) and did not alter
cytoplasmic localization of myc-tagged LRRK1 (Fig. 4c).
Like others [23, 24], we could not detect LRRK1 kinase
activity above the background and could not determine
whether activity was altered by the variants.
Discussion
In an unbiased, whole exome approach, we identified a variant
in LRRK1 (p.Arg1261Gln) as a candidate for a potentially
causal variant in familial PD. Although this finding is
intriguing and functionally plausible, we are unable to
conclude that this is indeed the cause of PD in our family.
For one, the variant was found in both cases and controls in
our larger case/control sample. Yet, the actual variant
frequency in controls appears to be lower than that found in
the KORA-AGE cohort (8 in 1,014 KORA-AGE vs. 0 in 1,
000 genomes, 1 in 1,076 in-house exomes, and 1 in additional
680 KORA controls), and it could be possible that KORA-
Fig. 4 Cellular expression of
LRRK1 and mutant variants. a
Western blot analysis of myc-
tagged LRRK1 expression in
SHSY5Y cells with beta actin-
loading control. b Analysis of
LRRK1 toxicity as measured by
MTT assay in SHSY5Y cells. No
significant toxicity was associated
with wild-type LRRK1, artificial
mutations in LRRK1, or disease-
associated coding changes. Data is
expressed as percentage of
untransfected control cells, mean,
and standard error measurement
displayed. c Immunocytochemistry
analysis of myc-tagged LRRK1
constructs. Staining for myc is
shown separately and merged. All
tagged constructs displayed a
diffuse cytoplasmic staining pattern.
Scale bar=20 μm
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AGE is enriched for the LRRK1 p.Arg1261Gln variant due to
a founder effect or that is also present in controls because its
PD-related nature depends on a specific genetic context.
Secondly, the other 14 identified rare variants shared by all
three affected individuals also represent potential candidates.
Especially, EEF1D p.Ala549Val, which was not found again
in any individual genotyped (n =3064, case/control sample
and in-house exomes) or the 1,000 genomes or the NHLBI-
ESP exomes, represents another good contender. In general,
these findings draw attention to the fact that in many cases,
very large populations will need to be evaluated to
conclusively judge the disease-related nature of a rare variant
such as those identified by exome sequencing. Most recent
studies show that while the power to detect associations for
genes harboring rare variants varies widely across genes, only
<5% of genes achieved 80% power even assuming high odds
ratios (OR) of 5 when tested in 400 cases and 400 controls
[25]. Ultimately, it is also possible that the truly causal variant
was not picked up in this study because it lies outside the
targeted regions of the exome.
The fact that both the LRRK1 and EEF1D variants were
also found in three unaffected members of the family each per
se does not contradict potential causality as it is known from
other autosomal dominant forms of PD that even among
members of a single family, penetrance of known PD
mutations can vary widely. Of individuals who harbor the
LRRK2 p.Gly2019Ser mutation, for example, only 28 % will
develop PD by the age of 59 years [26]. Thus, predicted
penetrances of the variants identified in our family are in line
with what is reported in the literature for other forms of
autosomal dominant PD.
Both LRRK1 and LRRK2 belong to the Roco family of
proteins. These proteins are likely to perform a number of
different functions as they are not only characterized by a
conserved Ras-like GTPase domain called ROC and a
characteristic COR domain of unknown function but also
harbor kinase and protein–protein interaction domains [27].
While a contribution of mutations in LRRK2 to disease
development in PD seems firmly established, the role of
LRRK2 paralog LRRK1 is unclear. It is known that LRRK1
and LRRK2 form heterodimers in HEK293T cells [21, 22]
and that both proteins are expressed in similar tissues.
Accordingly, a hypothetical role for LRRK1 in addition to
LRRK2 is plausible.
The precise role of LRRK2 in PD pathogenesis, however,
has not been fully established. Accordingly, even if one were
to assume a similar role of LRRK1 in disease development,
exactly which function of the protein would be involved in the
disease is uncertain. Therefore, the lack of a functional effect
on protein expression levels, subcellular localization, and cell
viability of the LRRK1 variants we identified does not equate
to a definitely missing role of LRRK1 in PD. Interestingly,
Lrrk1 has also been implicated in a quantitative trait locus for
dopaminergic amacrine cell number in the murine retina [28].
Further, the recent link between LRRK1 and endosomal
protein trafficking [18, 29] is also very intriguing in light of
the fact that one of the postulated pathomechanisms for
LRRK2 in PD involves aberrant lysosomal function or
localization [20, 30, 31].
However, studies addressing the role of both common and
rare genetic variants in LRRK1 with regard to PD do not seem
to substantiate the conception of LRRK1 as a “PD gene” [21,
32–34]. While none of these studies found a common or rare
variant clearly linked to PD, nonetheless, across three studies
([32, 34] and our study), the p.Thr967Met variant has only
been identified in seven out of 1,552 cases but not in any of 1,
535 controls (p nominal≤0.01, χ2 test; not significant after
correction for multiple testing, OR=14.90 (95 % confidence
interval=0.85 to 261.18)). Yet, in a family with multiple
individuals with PD, the variant did not segregate with the
phenotype [34]. Evidence also suggests that variants in
LRRK1 are able to modify the PD phenotype. Tunisian
individuals with LRRK2 p.Gly2019Ser showed a trend
towards a 6-year earlier age of onset when they also carried
LRRK1 p.Leu416Met [20]. In line with this, it has been
demonstrated for other genetic disorders that genetic variants
at related loci can both drive and modify a given phenotype
depending on the variant and the genetic context [35]. At the
moment, both functional and genetic data addressing a role of
LRRK1 as a PD gene are inconclusive. Nonetheless, it is
interesting that in our unbiased whole exome approach, one
of the top candidate variants for a genetic factor underlying or
contributing to the PD phenotype in our family is a non-
synonymous variant in the kinase domain of LRRK1 and that
other individuals suffering from PD harbor LRRK1 variants
(p.Tyr1410Asp) only with one amino acid away from the
location which is equivalent to the prominent p.Gly2019Ser
mutation of LRRK2 .
In summary, all variants shared by the three affected
individuals in our family represent potential causal or
modifying alleles in PD. As is the case for all rare and very
rare variants, establishing definitive causality is difficult, and
only the identification of additional PD families harboring
these variants or their analysis in sufficiently powered case/
control studies will tell whether these variants do indeed hold
a role in bringing about PD.
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